WARNING: CYTOKINE RELEASE SYNDROME and IMMUNE EFFECOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

See full prescribing information for complete boxed warning.

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosing schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity. (2.1, 2.2, 2.6, 5.1)

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity. (2.1, 2.2, 2.6, 5.2)

----------------------- INDICATIONS AND USAGE -----------------------

EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (1)

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

----------------------- DOSAGE AND ADMINISTRATION -----------------------

• For subcutaneous injection only. (2.2)
• Recommended Dosage: (2.2)

<table>
<thead>
<tr>
<th>Cycle of treatment</th>
<th>Day of treatment</th>
<th>Dose of EPKINLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>1</td>
<td>0.16 mg</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>0.8 mg</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>48 mg</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycles 2 and 3</td>
<td>1, 8, 15 and 22</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycles 4 to 9</td>
<td>1 and 15</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycle 10 and beyond</td>
<td>1</td>
<td>48 mg</td>
</tr>
</tbody>
</table>

* Cycle = 28 days

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
9 DOSAGE AND ADMINISTRATION
10 CLINICAL PHARMACOLOGY
11 DESCRIPTION
12 NONCLINICAL TOXICOLOGY
13 CLINICAL STUDIES
14 HOW SUPPLIED/STORAGE AND HANDLING
15 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosing schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1, 2.2, 2.6) and Warnings and Precautions (5.1)].

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1, 2.2, 2.6) and Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosing Information

- Administer EPKINLY to well-hydrated patients.

- Premedicate before each dose in Cycle 1 [see Dosage and Administration (2.4)].

- EPKINLY should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [see Warnings and Precautions (5.1, 5.2)].

- Administer EPKINLY subcutaneously according to the dosage schedule in Table 1 to reduce the incidence and severity of CRS. Due to the risk of CRS and ICANS, patients should be hospitalized for 24 hours after administration of the Cycle 1 Day 15 dosage of 48 mg [see Dosage and Administration (2.2) and Warnings and Precautions (5.1, 5.2)].
2.2 Recommended Dosage

EPKINLY is for subcutaneous injection only.

The recommended dosage schedule for EPKINLY is provided in Table 1. Administer EPKINLY in 28-day cycles until disease progression or unacceptable toxicity.

Table 1: EPKINLY Dosage Schedule

<table>
<thead>
<tr>
<th>Cycle of treatment</th>
<th>Day of treatment</th>
<th>Dose of EPKINLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>1</td>
<td>Step-up dose 1 0.16 mg</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Step-up dose 2 0.8 mg</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>First full dose 48 mg</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycles 2 and 3</td>
<td>1, 8, 15 and 22</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycles 4 to 9</td>
<td>1 and 15</td>
<td>48 mg</td>
</tr>
<tr>
<td>Cycle 10 and beyond</td>
<td>1</td>
<td>48 mg</td>
</tr>
</tbody>
</table>

* Cycle = 28 days

2.3 Restarting EPKINLY after Dosage Delay

If a dose of EPKINLY is delayed, restart therapy based on the recommendations made in Table 2 and resume the treatment schedule accordingly [see Dosage and Administration (2.2)].

Table 2: Recommendations for Restarting Therapy with EPKINLY After Dosage Delay

<table>
<thead>
<tr>
<th>Last Dose Administered</th>
<th>Time Since the Last Dose Administered</th>
<th>Action for Next Dose(s)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.16 mg on Cycle 1 Day 1</td>
<td>More than 8 days</td>
<td>Repeat 0.16 mg, then administer 0.8 mg the following week, followed by two weekly doses of 48 mg. Then resume the planned dosage schedule beginning with Day 1 of the subsequent cycle.</td>
</tr>
<tr>
<td>0.8 mg on Cycle 1 Day 8</td>
<td>14 days or less</td>
<td>Administer 48 mg then resume the recommended dosage schedule.</td>
</tr>
<tr>
<td></td>
<td>More than 14 days</td>
<td>Repeat 0.16 mg, then administer 0.8 mg the following week, followed by two weekly doses of 48 mg. Then resume the planned dosage schedule beginning with Day 1 of the subsequent cycle.</td>
</tr>
<tr>
<td>48 mg on Cycle 1 Day 15 onwards</td>
<td>6 weeks or less</td>
<td>Administer 48 mg, then resume the recommended dosage schedule.</td>
</tr>
<tr>
<td></td>
<td>More than 6 weeks</td>
<td>Repeat 0.16 mg, then administer 0.8 mg the following week, followed by two weekly doses of 48 mg. Then resume the planned dosage schedule.</td>
</tr>
</tbody>
</table>
2.4 Recommended Premedications

Administer premedications as outlined in Table 3 to reduce the risk of CRS [see Warnings and Precautions (5.1)].

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Patients requiring premedication</th>
<th>Premedication</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>All patients</td>
<td>• Prednisolone (100 mg oral or intravenous) or Dexamethasone (15 mg oral or intravenous) or equivalent</td>
<td>• 30-120 minutes prior to each weekly administration of EPKINLY&lt;br&gt;• And for three consecutive days following each weekly administration of EPKINLY in Cycle 1&lt;br&gt;• Diphenhydramine (50 mg oral or intravenous) or equivalent&lt;br&gt;• Acetaminophen (650 to 1,000 mg oral)</td>
</tr>
<tr>
<td>Cycle 2+</td>
<td>Patients who experienced Grade 2 or 3(^a) CRS with previous dose</td>
<td>• Prednisolone (100 mg oral or intravenous) or Dexamethasone (15 mg oral or intravenous) or equivalent</td>
<td>• 30-120 minutes prior to next administration of EPKINLY after a Grade 2 or 3(^a) CRS event&lt;br&gt;• And for three consecutive days following the next administration of EPKINLY until EPKINLY is given without subsequent CRS of Grade 2 or higher</td>
</tr>
</tbody>
</table>

\(^a\) Patients will be permanently discontinued from EPKINLY after Grade 4 CRS.

\(^a\) Administer pretreatment medication prior to EPKINLY dose and monitor patients accordingly [see Dosage and Administration (2.4, 2.6)].
2.5 Recommended Prophylaxis

*Pneumocystis jirovecii pneumonia (PJP)*
Provide PJP prophylaxis prior to starting treatment with EPKINLY.

*Herpes virus*
Consider initiating prophylaxis against herpes virus prior to starting EPKINLY to prevent herpes zoster reactivation.

2.6 Dosage Modifications and Management of Adverse Reactions

See Tables 4 and 5 for recommended actions for adverse reactions of CRS and ICANS, respectively. See Table 6 for recommended actions for other adverse reactions following administration of EPKINLY.

**Cytokine Release Syndrome (CRS)**
Identify CRS based on clinical presentation [*see Warnings and Precautions (5.1)*]. Evaluate for and treat other causes of fever, hypotension, and hypoxia.

If CRS is suspected, withhold EPKINLY until CRS resolves. Manage according to the recommendations in Table 4 and consider further management per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS.

**Table 4: Recommendations for Management of Cytokine Release Syndrome**

<table>
<thead>
<tr>
<th>Grade*</th>
<th>Presenting Symptoms</th>
<th>Actions</th>
</tr>
</thead>
</table>
| **Grade 1** | Temperature ≥ 100.4°F (38°C)*<sup>b</sup> | • Withhold EPKINLY and manage per current practice guidelines.  
• Ensure CRS symptoms are resolved prior to next dose of EPKINLY.*<sup>c</sup> |
| **Grade 2** | Temperature ≥ 100.4°F (38°C)*<sup>b</sup> with:  
Hypotension not requiring vaspressors and/or  
Hypoxia requiring low-flow oxygen*<sup>c</sup> by nasal cannula or blow-by. | • Withhold EPKINLY and manage per current practice guidelines.  
• Ensure CRS symptoms are resolved prior to next dose of EPKINLY.*<sup>c</sup>  
• Administer premedication*<sup>d</sup> prior to next dose of EPKINLY.  
• For the next dose of EPKINLY, monitor more frequently and consider hospitalization. |
<table>
<thead>
<tr>
<th>Grade&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Presenting Symptoms</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3</td>
<td>Temperature ≥ 100.4°F (38°C)&lt;sup&gt;b&lt;/sup&gt; with: Hypotension requiring a vasopressor (with or without vasopressin) and/or Hypoxia requiring high-flow oxygen&lt;sup&gt;c&lt;/sup&gt; by nasal cannula, face mask, non-rebreather mask, or Venturi mask.</td>
<td>• Withhold EPKINLY and manage per current practice guidelines, which may include intensive care. • Ensure CRS symptoms are resolved prior to the next dose of EPKINLY.&lt;sup&gt;c&lt;/sup&gt; • Administer premedication&lt;sup&gt;d&lt;/sup&gt; prior to next dose of EPKINLY. • Hospitalize for the next dose of EPKINLY.</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Temperature ≥ 100.4°F (38°C)&lt;sup&gt;b&lt;/sup&gt; with: Hypotension requiring multiple vasopressors (excluding vasopressin) and/or Hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation).</td>
<td>• Permanently discontinue EPKINLY. • Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.</td>
</tr>
</tbody>
</table>

<sup>a</sup> Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS.

<sup>b</sup> Premedication may mask fever, therefore if clinical presentation is consistent with CRS, follow these management guidelines.

<sup>c</sup> Refer to Table 2 for information on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].

<sup>d</sup> If Grade 2 or 3 CRS occurs with the second full dose (48 mg) or beyond, administer CRS premedications with each subsequent dose until a EPKINLY dose is given without subsequent CRS of Grade 2 or higher. Refer to Table 3 for additional information on premedication.

<sup>e</sup> Low-flow oxygen defined as oxygen delivered at < 6L/minute; high-flow oxygen defined as oxygen delivered at ≥ 6 L/minute.

---

**Immune Effector Cell-Associated Neurological Toxicity Syndrome (ICANS)**

Monitor patients for signs and symptoms of ICANS [see Warnings and Precautions (5.2)]. At the first sign of ICANS, withhold EPKINLY and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care, for ICANS [see Warnings and Precautions (5.2)]. Manage ICANS according to the recommendations in Table 5 and consider further management per current practice guidelines.
Table 5: Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome

<table>
<thead>
<tr>
<th>Grade</th>
<th>Presenting Symptoms</th>
<th>Actions</th>
</tr>
</thead>
</table>
| **Grade 1** | ICE score 7-9, Or depressed level of consciousness: awakens spontaneously. | • Withhold EPKINLY until ICANS resolves.  
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. |
| **Grade 2** | ICE score 3-6, Or depressed level of consciousness: awakens to voice. | • Withhold EPKINLY until ICANS resolves.  
  • Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.  
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. |
| **Grade 3** | ICE score 0-2, Or depressed level of consciousness: awakens only to tactile stimulus, Or seizures, either:  
  • Any clinical seizure, focal or generalized, that resolves rapidly, or  
  • Non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, Or raised intracranial pressure: focal/local edema on neuroimaging. | First Occurrence of Grade 3 ICANS  
  • Withhold EPKINLY until ICANS resolves.  
  • Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.  
  • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.  
  • Provide supportive therapy, which may include intensive care.  

Recurrent Grade 3 ICANS  
• Permanently discontinue EPKINLY  
• Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.
<table>
<thead>
<tr>
<th>Grade&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Presenting Symptoms&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Actions</th>
</tr>
</thead>
</table>
|                 |                               | • Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.  
• Provide supportive therapy, which may include intensive care. |
| Grade 4         | ICE score 0<sup>c</sup>, Or depressed level of consciousness<sup>d</sup>, either:  
• Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or  
• Stupor or coma  
Or seizures, either:  
• Life-threatening prolonged seizure (> 5 minutes), or  
• Repetitive clinical or electrical seizures without return to baseline in between,  
Or motor findings<sup>d</sup>:  
• Deep focal motor weakness, such as hemiparesis or paraparesis, or raised intracranial pressure/cerebral edema, with signs/symptoms such as:  
• Diffuse cerebral edema on neuroimaging, or  
• Decerebrate or decorticate posturing, or  
• Cranial nerve VI palsy, or  
• Papilledema, or  
• Cushing’s triad. | • Permanently discontinue EPKINLY.  
• Administer dexamethasone<sup>f</sup> 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.  
• Alternatively, consider administration of methylprednisolone 1,000 mg per day intravenously and continue methylprednisolone 1,000 mg per day intravenously for 2 or more days.  
• Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.  
• Provide supportive therapy, which may include intensive care. |

<sup>a</sup> Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS.  
<sup>b</sup> Management is determined by the most severe event, not attributable to any other cause.  
<sup>c</sup> If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (names 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards
<table>
<thead>
<tr>
<th>Grade^a</th>
<th>Presenting Symptoms^b</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>from 100 by ten = 1 point. If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not attributable to any other cause.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>See Table 2 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All references to dexamethasone administration are dexamethasone or equivalent.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6: Recommended Dosage Modifications for Other Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reaction^1</th>
<th>Severity^1</th>
<th>Action</th>
</tr>
</thead>
</table>
| Infections [see Warnings and Precautions (5.3)] | Grades 1-4 | • Withhold EPKINLY in patients with active infection, until the infection resolves.\(^2\)  
• For Grade 4, consider permanent discontinuation of EPKINLY. |
| Neutropenia [see Warnings and Precautions (5.4)] | Absolute neutrophil count less than 0.5 x 10^9/L | • Withhold EPKINLY until absolute neutrophil count is 0.5 x 10^9/L or higher.\(^2\) |
| Thrombocytopenia [see Warnings and Precautions (5.4)] | Platelet count less than 50 x 10^9/L | • Withhold EPKINLY until platelet count is 50 x 10^9/L or higher.\(^2\) |
| Other Adverse Reactions [see Adverse Reactions (6.1)] | Grade 3 or higher | • Withhold EPKINLY until the toxicity resolves to Grade 1 or baseline.\(^2\) |

\(^1\) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.  
\(^2\) See Table 2 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].

2.7 Preparation and Administration

Read this entire section carefully before preparation of EPKINLY. Certain doses of EPKINLY require dilution prior to administration. Follow the preparation instructions provided below, as improper preparation may lead to improper dose.

EPKINLY is prepared and administered by a healthcare provider as a subcutaneous injection. The administration of EPKINLY takes place over the course of 28-day cycles, following the dosage schedule in Section 2.2.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Preparation of EPKINLY

Use aseptic technique to prepare EPKINLY. Filtration of the diluted solution is not required.
**Preparation instructions for 0.16 mg and 0.8 mg dose of EPKINLY**

**0.16 mg Dose Preparation Instructions (2 dilutions required)**

Use an appropriately sized syringe, vial, and needle for each transfer step.

1. Prepare EPKINLY vial
   a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.
   b. Allow the vial to come to room temperature for no more than 1 hour.
   c. Gently swirl the EPKINLY vial.
   **DO NOT** invert, vortex, or vigorously shake the vial.

2. Perform first dilution
   a. Label an appropriately sized empty vial as “Dilution A.”
   b. Transfer **0.8 mL of EPKINLY** into the Dilution A vial.
   c. Transfer **4.2 mL of 0.9% Sodium Chloride Injection, USP** into the Dilution A vial.
      The initially diluted solution contains 0.8 mg/mL of EPKINLY.
   d. Gently swirl the Dilution A vial for 30 to 45 seconds.

3. Perform second dilution
   a. Label an appropriately sized empty vial as “Dilution B.”
   b. Transfer **2 mL of solution** from the Dilution A vial into the Dilution B vial. The Dilution A vial is no longer needed.
   c. Transfer **8 mL of 0.9% Sodium Chloride Injection, USP** into the Dilution B vial to make a final concentration of 0.16 mg/mL.
   d. Gently swirl the Dilution B vial for 30 to 45 seconds.

4. Withdraw dose
   a. Withdraw **1 mL of the diluted EPKINLY** from the Dilution B vial into a syringe.

5. Label syringe
   a. Label the syringe with the dose strength (0.16 mg) and the time of day.

Discard the vial containing unused EPKINLY.

**0.8 mg Dose Preparation Instructions (1 dilution required)**

Use an appropriately sized syringe, vial, and needle for each transfer step.

1. Prepare EPKINLY vial
   a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.
   b. Allow the vial to come to room temperature for no more than 1 hour.
   c. Gently swirl the EPKINLY vial.
   **DO NOT** invert, vortex, or vigorously shake the vial.

2. Perform dilution
   a. Label an appropriately sized empty vial as “Dilution A.”
b. Transfer **0.8 mL** of **EPKINLY** into the **Dilution A** vial.

c. Transfer **4.2 mL** of **0.9% Sodium Chloride Injection, USP** into the **Dilution A** vial to make a final concentration of 0.8 mg/mL.

d. Gently swirl the **Dilution A** vial for 30 to 45 seconds.

3. **Withdraw dose**
   
a. **Withdraw 1 mL of the diluted EPKINLY** from the **Dilution A** vial into a syringe.

4. **Label syringe**
   
a. Label the syringe with the dose strength (0.8 mg) and the time of day.

Discard the vial containing unused EPKINLY.

**48 mg Dose Preparation Instructions (No dilution required)**

EPKINLY 48 mg/0.8 mL vial is supplied as ready-to-use solution that does not need dilution prior to administration.

1. **Prepare EPKINLY vial**
   
a. Retrieve one 48 mg/0.8 mL EPKINLY vial from the refrigerator.

b. Allow the vial to come to room temperature for no more than 1 hour.

c. Gently swirl the EPKINLY vial.

**DO NOT** invert, vortex, or vigorously shake the vial.

2. **Withdraw dose**
   
a. **Withdraw 0.8 mL of EPKINLY** into a syringe.

3. **Label syringe**
   
a. Label the syringe with the dose strength (48 mg) and the time of day.

Discard the vial containing unused EPKINLY.

**Diluted EPKINLY Storage**

Use diluted EPKINLY solution immediately. If not used immediately, store the solution refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature at 20°C to 25°C (68°F to 77°F) for up to 12 hours. The total storage time from the start of dose preparation to administration should not exceed 24 hours. Protect from direct sunlight. Allow EPKINLY solution to equilibrate to room temperature for no more than 1 hour before administration. Discard unused EPKINLY solution beyond the allowable storage time.

**Administration**

Inject the required volume of EPKINLY into the subcutaneous tissue of the lower part of the abdomen (preferred injection site) or the thigh. Change of injection site from the left or right side or vice versa is recommended, especially during the weekly administrations (Cycles 1 to 3).

Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard, or not intact.
3  DOSAGE FORMS AND STRENGTHS

EPKINLY is a clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous injection:

- Injection: 4 mg/0.8 mL in a single-dose vial, which must be diluted prior to use
- Injection: 48 mg/0.8 mL in a single-dose vial

4  CONTRAINDICATIONS

None.

5  WARNINGS AND PRECAUTIONS

5.1 Cytokine Release Syndrome

EPKINLY can cause CRS, including serious or life-threatening reactions [see Adverse Reactions (6.1)].

Cytokine release syndrome occurred in 51% of patients receiving EPKINLY at the recommended dose in the clinical trial, with Grade 1 CRS occurring in 37%, Grade 2 in 17%, and Grade 3 in 2.5% of patients. Recurrent CRS occurred in 16% of patients. Of all the CRS events, most (92%) occurred during Cycle 1. In Cycle 1, 9% of CRS events occurred after the 0.16 mg dose on Cycle 1 Day 1, 16% after the 0.8 mg dose on Cycle 1 Day 8, 61% after the 48 mg dose on Cycle 1 Day 15, and 6% after the 48 mg dose on Cycle 1 Day 22.

The median time to onset of CRS from the most recent administered EPKINLY dose across all doses was 24 hours (range: 0 to 10 days). The median time to onset after the first full 48 mg dose was 21 hours (range: 0 to 7 days). CRS resolved in 98% of patients and the median duration of CRS events was 2 days (range: 1 to 27 days).

In patients who experienced CRS, the signs and symptoms included pyrexia, hypotension, hypoxia, dyspnea, chills, and tachycardia. Concurrent neurological adverse reactions associated with CRS occurred in 2.5% of patients and included headache, confusional state, tremors, dizziness, and ataxia.

Initiate therapy according to EPKINLY step-up dosing schedule. Administer pretreatment medications to reduce the risk of CRS and monitor patients for potential CRS following EPKINLY accordingly. Following administration of the first 48 mg dose, patients should be hospitalized for 24 hours [see Dosage and Administration (2.2, 2.3, 2.4)]. At the first signs or symptoms of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care as appropriate. Withhold or discontinue EPKINLY based on the severity of CRS [see Dosage and Administration (2.6)].
Patients who experience CRS (or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.

5.2 Immune Effector Cell-Associated Neurotoxicity Syndrome

EPKINLY can cause life-threatening and fatal immune effector cell-associated neurotoxicity syndrome (ICANS) [see Adverse Reactions (6.1)].

Immune Effector Cell-Associated Neurotoxicity Syndrome occurred in 6% (10/157) of patients receiving EPKINLY at the recommended dose in the clinical trial, with Grade 1 ICANS in 4.5% and Grade 2 ICANS in 1.3% of patients. There was one (0.6%) fatal ICANS occurrence. Of the 10 ICANS events, 9 occurred within Cycle 1 of EPKINLY treatment, with a median time to onset of ICANS of 16.5 days (range: 8 to 141 days) from the start of treatment. Relative to the most recent administration of EPKINLY, the median time to onset of ICANS was 3 days (range: 1 to 13 days). The median duration of ICANS was 4 days (range: 0 to 8 days) with ICANS resolving in 90% of patients with supportive care. Clinical manifestations of ICANS included, but were not limited to, confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

Monitor patients for potential ICANS following EPKINLY. At the first signs or symptoms of ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or discontinue EPKINLY per recommendations and consider further management per current practice guidelines [see Dosage and Administration (2.6)].

Patients who experience signs or symptoms of ICANS or any other adverse reactions that impair cognition or consciousness should be evaluated, including potential neurology evaluation, and patients at increased risk should be advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.

5.3 Infections

EPKINLY can cause serious and fatal infections [see Adverse Reactions (6.1)].

In the clinical trial, serious infections, including opportunistic infections, were reported in 15% of patients treated with EPKINLY at the recommended dose with Grade 3 or 4 infections in 14% and fatal infections in 1.3%. The most common Grade 3 or greater infections were sepsis, COVID-19, urinary tract infection, pneumonia, and upper respiratory tract infection.

Monitor patients for signs and symptoms of infection prior to and during treatment with EPKINLY and treat appropriately. Avoid administration of EPKINLY in patients with active infections. Provide PJP prophylaxis prior to initiating treatment with EPKINLY; consider initiating prophylaxis against herpes virus prior to starting EPKINLY [see Dosage and Administration (2.5)].
Withhold or consider permanent discontinuation of EPKINLY based on severity [see Dosage and Administration (2.6)].

5.4 Cytopenias

EPKINLY can cause serious or severe cytopenias, including neutropenia, anemia, and thrombocytopenia [see Adverse Reactions (6.1)].

Among patients who received the recommended dosage in the clinical trial, Grade 3 or 4 decreased neutrophils occurred in 32%, decreased hemoglobin in 12%, and decreased platelets in 12% of patients. Febrile neutropenia occurred in 2.5%.

Monitor complete blood counts throughout treatment. Based on the severity of cytopenias, temporarily withhold or permanently discontinue EPKINLY [see Dosage and Administration (2.6)]. Consider prophylactic granulocyte colony-stimulating factor administration as applicable.

5.5 Embryo-Fetal Toxicity

Based on its mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Cytokine Release Syndrome [see Warnings and Precautions (5.1)].
- Immune Effector Cell-Associated Neurotoxicity Syndrome [see Warnings and Precautions (5.2)].
- Infections [see Warnings and Precautions (5.3)].
- Cytopenias [see Warnings and Precautions (5.4)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Relapsed or Refractory Large B-cell Lymphoma (LBCL)

_EPCORE NHL-1_

The safety of EPKINLY was evaluated in EPCORE NHL-1, a single-arm study of patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including DLBCL not
otherwise specified, DLBCL arising from indolent lymphoma, high grade B-cell lymphoma, and other B-cell lymphomas [see Clinical Studies (14)]. A total of 157 patients received EPKINLY via subcutaneous injection until disease progression or unacceptable toxicities according to the following 28-day cycle schedule:

- Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22
- Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22
- Cycles 4-9: EPKINLY 48 mg on Days 1 and 15
- Cycles 10 and beyond: EPKINLY 48 mg on Day 1

Of the 157 patients treated, the median age was 64 years (range: 20 to 83), 60% male, and 97% had an ECOG performance status of 0 or 1. Race was reported in 133 (85%) patients; of these patients, 61% were White, 19% were Asian, and 0.6% were Native Hawaiian or Other Pacific Islander. There were no Black or African American or Hispanic or Latino patients treated in the clinical trial as reported. The median number of prior therapies was 3 (range: 2 to 11). The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, an ongoing active infection, and any patients with known impaired T-cell immunity.

The median duration of exposure for patients receiving EPKINLY was 5 cycles (range: 1 to 20 cycles).

Serious adverse reactions occurred in 54% of patients who received EPKINLY. Serious adverse reactions in ≥ 2% of patients included CRS, infections (including sepsis, COVID-19, pneumonia, and upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, and ICANS. Fatal adverse reactions occurred in 3.8% of patients who received EPKINLY, including COVID-19 (1.3%), hepatotoxicity (0.6%), ICANS (0.6%), myocardial infarction (0.6%), and pulmonary embolism (0.6%).

Permanent discontinuation of EPKINLY due to an adverse reaction occurred in 3.8% of patients. Adverse reactions which resulted in permanent discontinuation of EPKINLY included COVID-19, CRS, ICANS, pleural effusion, and fatigue.

Dosage interruptions of EPKINLY due to an adverse reaction occurred in 34% of patients who received EPKINLY. Adverse reactions which required dosage interruption in ≥ 3% of patients included CRS, neutropenia, sepsis, and thrombocytopenia.

The most common (≥ 20%) adverse reactions were CRS, fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, and decreased platelets.
Table 7 summarizes the adverse reactions in EPCORE NHL-1.

<table>
<thead>
<tr>
<th>Adverse Reaction§</th>
<th>EPKINLY (N=157)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine release syndrome*</td>
<td>51</td>
<td>2.5#</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatiguea</td>
<td>29</td>
<td>2.5#</td>
</tr>
<tr>
<td>Injection site reactionsb</td>
<td>27</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>Edema^c</td>
<td>14</td>
<td>1.9#</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal paind</td>
<td>28</td>
<td>1.3#</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal paine</td>
<td>23</td>
<td>1.9#</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>20</td>
<td>1.3#</td>
</tr>
<tr>
<td>Vomiting</td>
<td>12</td>
<td>0.6#</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rashf</td>
<td>15</td>
<td>0.6#</td>
</tr>
<tr>
<td><strong>Nervous system disorder</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>13</td>
<td>0.6#</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>12</td>
<td>0.6#</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac arrhythmias§</td>
<td>10</td>
<td>0.6#</td>
</tr>
</tbody>
</table>

§ Adverse reactions were graded based on CTCAE Version 5.0
* Only grade 3 adverse reactions occurred.
# CRS was graded using ASTCT consensus criteria (Lee et al., 2019).
^ Fatigue includes asthenia, fatigue, lethargy.
b Injection site reactions includes injection site erythema, injection site hypertrophy, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticaria.
^ Edema includes edema, edema peripheral, face edema, generalized edema, peripheral swelling.
d Musculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain, pain in extremity, spinal pain.
e Abdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness.
Rash includes dermatitis bullous, erythema, palmar erythema, penile erythema, rash, rash erythematous, rash maculo-papular, rash pustular, recall phenomenon, seborrheic dermatitis, skin exfoliation.
§ Cardiac arrhythmias includes bradycardia, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, supraventricular tachycardia, tachycardia.
Clinically relevant adverse reactions in < 10% of patients who received EPKINLY included ICANS, sepsis, pleural effusion, COVID-19, pneumonia (including pneumonia and COVID-19 pneumonia), tumor flare, febrile neutropenia, upper respiratory tract infections, and tumor lysis syndrome.

Table 8 summarizes laboratory abnormalities in EPCORE NHL-1.

**Table 8: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Relapsed or Refractory LBCL Who Received EPKINLY in EPCORE NHL-1**

<table>
<thead>
<tr>
<th>Laboratory Abnormality*</th>
<th>EPKINLY&lt;sup&gt;1&lt;/sup&gt;</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count decreased</td>
<td>87</td>
<td>77</td>
</tr>
<tr>
<td>Hemoglobin decreased</td>
<td>62</td>
<td>12</td>
</tr>
<tr>
<td>White blood cells decreased</td>
<td>53</td>
<td>22</td>
</tr>
<tr>
<td>Neutrophils decreased</td>
<td>50</td>
<td>32</td>
</tr>
<tr>
<td>Platelets decreased</td>
<td>48</td>
<td>12</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium decreased</td>
<td>56</td>
<td>2.6</td>
</tr>
<tr>
<td>Phosphate decreased&lt;sup&gt;2&lt;/sup&gt;</td>
<td>56</td>
<td>N/A</td>
</tr>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>48</td>
<td>4.6</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>45</td>
<td>5.3</td>
</tr>
<tr>
<td>Potassium decreased</td>
<td>34</td>
<td>5.3</td>
</tr>
<tr>
<td>Magnesium decreased</td>
<td>31</td>
<td>0</td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>24</td>
<td>3.3</td>
</tr>
<tr>
<td>Potassium increased</td>
<td>21</td>
<td>1.3</td>
</tr>
</tbody>
</table>

* Laboratory abnormalities were graded based on CTCAE Version 5.0
<sup>1</sup> The denominator used to calculate the rate varied from 146 to 153 based on the number of patients with a baseline value and at least one post-treatment value.
<sup>2</sup> CTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN).

7 **DRUG INTERACTIONS**

For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.

Epcoritamab-bypca causes release of cytokines [see Clinical Pharmacology (12.2)] that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY on Cycle 1 Day 1 and up to 14 days after the first 48 mg dose on Cycle 1 Day 15, and during and after CRS [see Warnings and Precautions (5.1)].
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
Based on the mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of EPKINLY in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with epcoritamab-bysp.

Epcoritamab-bysp causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, epcoritamab-bysp can cause B-cell lymphocytopenia in infants exposed to epcoritamab-bysp in-utero. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, EPKINLY has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

Risk Summary
There is no information regarding the presence of epcoritamab-bysp in human milk, the effect on the breastfed child, or milk production. Because maternal IgG is present in human milk, and there is potential for epcoritamab-bysp absorption leading to serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with EPKINLY and for 4 months after the last dose.

8.3 Females and Males of Reproductive Potential

EPKINLY may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing
Verify pregnancy status in females of reproductive potential prior to initiating EPKINLY.

Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose.
8.4 Pediatric Use

The safety and efficacy of EPKINLY in pediatric patients have not been established.

8.5 Geriatric Use

In patients with relapsed or refractory LBCL who received EPKINLY in the clinical trial, 49% were 65 years of age or older, and 19% were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients 65 years of age or older compared with younger adult patients.

11 DESCRIPTION

Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager; it is a humanized bispecific IgG1 antibody. Epcoritamab-bysp is manufactured in Chinese hamster ovary (CHO) cells using recombinant DNA technology and has an approximate molecular weight of 149 kDa.

EPKINLY (epcoritamab-bysp) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, free of visible particles.

Each single-dose 4 mg/0.8 mL vial contains epcoritamab-bysp (4 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5.

Each single-dose 48 mg/0.8 mL vial contains epcoritamab-bysp (48 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells.

In vitro, epcoritamab-bysp activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.

12.2 Pharmacodynamics

Circulating B Cell Count
Circulating B cells decreased to undetectable levels (< 10 cells/microliter) after administration of the approved recommended dosage of EPKINLY in patients who had detectable B cells at
treatment initiation by Cycle 1 Day 15 (after the first full dose of 48 mg) and the depletion was sustained while patients remained on treatment.

Cytokine Concentrations
Plasma concentrations of cytokines (IL-2, IL-6, IL-10, TNF-α, and IFN-γ) were measured. Transient elevation of circulating cytokines was observed at dose levels of 0.04 mg and above. After administration of the approved recommended dosage of EPKINLY, the cytokine levels increased within 24 hours after the first dose on Cycle 1 Day 1, reached maximum levels after the first 48 mg dose on Cycle 1 Day 15, and returned to baseline prior to the next 48 mg full dose on Cycle 1 Day 22.

12.3 Pharmacokinetics
Pharmacokinetic (PK) parameters were evaluated at the approved recommended dosage (48 mg) and are presented as geometric mean (CV%) unless otherwise specified.

Epcoritamab-byps area under the concentration-time curve (AUC) increased more than proportionally over a full dosage range from 1.5 to 60 mg (0.03125 to 1.25 times the approved recommended dosage).

Epcoritamab-byps maximum concentration (11.1 mcg/mL [41.5%]) is achieved after the first dose of the Q2W regimen (i.e., after the 11th dose of 48 mg at the first dose of Cycle 4). PK exposures are summarized for the recommended dosage of EPKINLY in Table 9.

Table 9: Exposure Parameters of Epcoritamab-byps in Subjects with Relapsed or Refractory LBCL

<table>
<thead>
<tr>
<th></th>
<th>C_avg (mcg/mL)¹</th>
<th>C_max (mcg/mL)¹</th>
<th>C_trough (mcg/mL)¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>First full 48 mg dose</td>
<td>1.6 (72.4)</td>
<td>2.2 (70.0)</td>
<td>1.7 (74.0)</td>
</tr>
<tr>
<td>End of weekly dosing (end of Cycle 3)</td>
<td>9.9 (45.1)</td>
<td>10.8 (41.7)</td>
<td>8.4 (53.3)</td>
</tr>
<tr>
<td>End of every 2-week dosing (end of Cycle 9)</td>
<td>5.9 (49.3)</td>
<td>7.5 (41.1)</td>
<td>4.1 (73.9)</td>
</tr>
<tr>
<td>Steady state² with every 4-week dosing</td>
<td>2.7 (69.5)</td>
<td>4.8 (51.6)</td>
<td>1.2 (130)</td>
</tr>
</tbody>
</table>

¹ Values are geometric mean with geometric CV%
² Steady state values are approximated at Cycle 15 (Week 60)

Absorption
The median (range) Tmax of epcoritamab-byps after the first full dose and end of the weekly dosing regimen (end of Cycle 3) treatment doses were 4 (0.3 to 7) days and 2.3 (0.3 to 3.2) days, respectively.

Distribution
The apparent total volume of distribution is 25.6 L (82%).
**Elimination**
The half-life of full dose epcoritamab-bysp (48 mg) was approximately 22 days (58%) at the end of Cycle 3, with apparent total clearance of approximately 0.53 L/day (40%) after the end of Cycle 3.

**Metabolism**
Epcoritamab-bysp is expected to be metabolized into small peptides by catabolic pathways.

**Specific Populations**
No clinically significant differences in the PK of epcoritamab-bysp were observed based on age (20 to 89 years), sex, race (White or Asian), mild to moderate renal impairment (creatinine clearance [\(\text{CLcr}\) 30 to < 90 mL/min as estimated by Cockcroft-Gault formula), and mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin 1 to 1.5 times ULN and any AST) after accounting for differences in bodyweight.

The effects of severe renal impairment (\(\text{CLcr}\) 15 to < 30 mL/min), end-stage renal disease (\(\text{CLcr}\) < 15 mL/min), or moderate to severe hepatic impairment (total bilirubin > 1.5 times ULN and any AST) on the PK of epcoritamab-bysp are unknown.

**Body Weight**
In patients who received the recommended dosage of EPKINLY, Cycle 1 median average concentration was 13% lower in the higher body weight (BW) group (85 to 144 kg) and 37% higher in the lower BW group (39 to 65 kg) compared to patients with BW of 65 to less than 85 kg.

**Drug Interaction Studies**
No clinical studies evaluating the drug interaction potential of epcoritamab-bysp have been conducted.

**12.6 Immunogenicity**
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies (ADA) in the study described below with the incidence of ADA in other studies, including those of epcoritamab-bysp.

Anti-epcoritamab-bysp antibodies developed in 2.6% of patients (4 of 156) treated with EPKINLY at the recommended dosage during treatment in Study EPCORE NHL-1 (up to 10 cycles) [see Clinical Studies (14)] using an electrochemiluminescence immunoassay (ECLIA). Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the PK, pharmacodynamics, safety, and effectiveness of epcoritamab-bysp is unknown.
13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No carcinogenicity or genotoxicity studies have been conducted with epcoritamab-bysp.

No dedicated studies have been conducted to evaluate the effects of epcoritamab-bysp on fertility.

14 CLINICAL STUDIES

The efficacy of EPKINLY was evaluated in EPCORE NHL-1 (Study GCT3013-01; NCT03625037), an open-label, multi-cohort, multicenter, single-arm trial in 157 patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, ongoing active infection, and any patients with known impaired T-cell immunity. Patients received EPKINLY monotherapy as a subcutaneous injection according to the following 28-day cycle schedule:

- Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22
- Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22
- Cycles 4-9: EPKINLY 48 mg on Days 1 and 15
- Cycles 10 and beyond: EPKINLY 48 mg on Day 1

Patients continued to receive EPKINLY until disease progression or unacceptable toxicity. In the setting of a suspected tumor flare reaction, continued treatment was permitted.

The efficacy population includes 148 patients with DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma. Of the 148 patients, the median age was 65 years (range: 22 to 83), 62% were male, 97% had an ECOG performance status of 0 or 1, and 3% had an ECOG performance status of 2. Race was reported in 125 (84%) patients; of these patients, 61% were White, 20% were Asian, and 0.7% were Native Hawaiian or Other Pacific Islander. There were no Black or African American or Hispanic or Latino patients treated in the clinical trial as reported. The diagnosis was DLBCL NOS in 86%, including 27% with DLBCL transformed from indolent lymphoma, and high-grade B-cell lymphoma in 14%. The median number of prior therapies was 3 (range: 2 to 11), with 30% receiving 2 prior therapies, 30% receiving 3 prior therapies, and 40% receiving 4 or more prior therapies. Eighteen percent had prior autologous HSCT, and 39% had prior chimeric antigen receptor (CAR) T-cell therapy. Eighty-two percent of patients had disease refractory to last therapy and 29% of patients were refractory to CAR T-cell therapy.

Efficacy was established based on overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC) and duration of response. The efficacy results are summarized in Table 10.
Table 10: Efficacy Results in EPCORE NHL-1 in Patients with DLBCL and High-grade B-cell Lymphoma

<table>
<thead>
<tr>
<th>Endpoint(^a)</th>
<th>EPKINLY (N=148)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR(^b), n (%)</td>
<td>90 (61)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(52.5, 68.7)</td>
</tr>
<tr>
<td>CR, n (%)</td>
<td>56 (38)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(30.0, 46.2)</td>
</tr>
<tr>
<td>PR, n (%)</td>
<td>34 (23)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(16.5, 30.6)</td>
</tr>
<tr>
<td>DOR</td>
<td>15.6 (9.7, NR)</td>
</tr>
<tr>
<td>Median (95% CI), months</td>
<td></td>
</tr>
<tr>
<td>9-month estimate(^c) % (95% CI)</td>
<td>63 (51.5, 72.4)</td>
</tr>
</tbody>
</table>

ORR = overall response rate; CI = confidence interval; CR = complete response; PR = partial response; DOR = duration of response; NR = not reached.

\(^a\) Determined by Lugano criteria (2014) as assessed by independent review committee (IRC).

\(^b\) Early response assessments were evaluated in the context of potential flare reactions. Of 90 patients who achieved an objective response, 9 patients had early flare reactions identified with objective response demonstrated on subsequent imaging per Lugano criteria.

\(^c\) Kaplan-Meier estimate.

The median time to response was 1.4 months (range: 1 to 8.4 months). Among responders, the median follow-up for DOR was 9.8 months (range: 0.0 to 17.3 months).

16  HOW SUPPLIED/STORAGE AND HANDLING

How Supplied
EPKINLY (epcoritamab-bysp) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, free of visible particles, supplied in glass vials as follows:

<table>
<thead>
<tr>
<th>Carton contents</th>
<th>NDC number</th>
</tr>
</thead>
<tbody>
<tr>
<td>One 4 mg/0.8 mL single-dose vial</td>
<td>NDC 82705-002-01</td>
</tr>
<tr>
<td>One 48 mg/0.8 mL single-dose vial</td>
<td>NDC 82705-010-01</td>
</tr>
</tbody>
</table>

The vial stopper is not made with natural rubber latex.

Storage and Handling
Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake.

17  PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Cytokine Release Syndrome (CRS)
Inform patients of the risk of CRS, and to immediately contact their healthcare provider should signs and symptoms associated with CRS (e.g., pyrexia, hypotension, hypoxia, chills, tachycardia, headache, and dyspnea) occur at any time. Advise patients that they should be hospitalized for 24 hours after administration of the Cycle 1 Day 15 dosage of 48 mg. Advise patients who experience symptoms that impair consciousness not to drive and refrain from operating heavy or potentially dangerous machinery until events resolve [see Warnings and Precautions (5.1)].

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Advise patients of the risk of ICANS, to immediately contact their healthcare provider for signs and symptoms associated with ICANS, which may manifest, for example, as confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus, and that the onset of events may be delayed. Advise patients who experience symptoms of ICANS that impair consciousness to refrain from driving or operating heavy or potentially dangerous machinery until symptoms of ICANS resolve [see Warnings and Precautions (5.2)].

Infections
Advise patients of the risk of serious infections, and to contact their healthcare professional for signs or symptoms of serious infection [see Warnings and Precautions (5.3)].

Cytopenias
Discuss the signs and symptoms associated with cytopenias, including neutropenia and febrile neutropenia, anemia, and thrombocytopenia [see Warnings and Precautions (5.4)].

Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider if they are pregnant or become pregnant [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.3)].

Lactation
Advise women not to breastfeed during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.2)].

Manufactured by:
Genmab US, Inc.
Plainsboro, NJ 08536, USA
1-855-4GENMAB (1-855-443-6622)
U.S. License Number: 2293

Marketed by:
Genmab US, Inc.
Plainsboro, NJ 08536
and
AbbVie Inc.
North Chicago, IL 60064

EPKINLY is a trademark owned by Genmab A/S

©2023 Genmab A/S
EPKINLY can cause serious side effects, including:

- **Cytokine Release Syndrome (CRS).** CRS is common during treatment with EPKINLY and can also be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:
  - fever of 100.4°F (38°C) or higher
  - dizziness or light-headedness
  - trouble breathing
  - chills
  - fast heartbeat
  - feeling anxious
  - headache
  - confusion
  - shaking (tremors)
  - problems with balance and movement, such as trouble walking

**Due to the risk of CRS, you will receive EPKINLY on a “step-up dosing schedule”**.
  - The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on Day 1 and Day 8 of your first cycle of treatment (Cycle 1).
  - You will receive your first full dose of EPKINLY on Day 15 of Cycle 1.
  - If your dose of EPKINLY is delayed for any reason, you may need to repeat the “step-up dosing schedule”.
  - Before each dose in Cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.
  - See “How will I receive EPKINLY?” for more information about how you will receive EPKINLY.

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:
  - trouble speaking or writing
  - confusion and disorientation
  - drowsiness
  - tiredness or lack of energy
  - muscle weakness
  - shaking (tremors)
  - seizures
  - memory loss

**Due to the risk of CRS and neurologic problems**, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on Day 15 of Cycle 1. Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

**See “What are the possible side effects of EPKINLY?”** for more information about side effects.

**What is EPKINLY?**

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have already received 2 or more treatments for their cancer.

It is not known if EPKINLY is safe and effective in children.

**Before receiving EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection.
- are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby.

**Females who are able to become pregnant:**
  - Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY.
  - You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY.
  - Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.

- are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of EPKINLY.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
### How will I receive EPKINLY?

- **EPKINLY** will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in the lower part of your stomach-area (abdomen) or thigh.
- Your **EPKINLY** treatment schedule is divided into cycles that are usually 28 days (4 weeks) long.
- **EPKINLY** is usually given every week during Cycles 1 to 3, every 2 weeks during Cycles 4 to 9, and every 4 weeks starting with Cycle 10.
- Your healthcare provider will decide how many treatment cycles you will receive.
- See “**What is the most important information I should know about EPKINLY?**” for more information about how you will receive **EPKINLY**.

### What should I avoid while receiving EPKINLY?

**Do not** drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.

See “**What is the most important information I should know about EPKINLY?**” for more information about signs and symptoms of CRS and neurologic problems.

### What are the possible side effects of EPKINLY?

**EPKINLY** can cause serious side effects, including:

- **Infections.** **EPKINLY** can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment with **EPKINLY**. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with **EPKINLY**, including:
  - fever of 100.4°F (38°C) or higher
  - cough
  - chest pain
  - tiredness
  - shortness of breath
  - painful rash
  - sore throat
  - pain during urination
  - feeling weak or generally unwell

- **Low blood cell counts.** Low blood cell counts are common during treatment with **EPKINLY** and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with **EPKINLY**. **EPKINLY** may cause the following low blood cell counts:
  - **low white blood cell counts (neutropenia).** Low white blood cells can increase your risk for infection.
  - **low red blood cell counts (anemia).** Low red blood cells can cause tiredness and shortness of breath.
  - **low platelet counts (thrombocytopenia).** Low platelet counts can cause bruising or bleeding problems.

Your healthcare provider may temporarily stop or completely stop treatment with **EPKINLY** if you develop certain side effects.

The **most common side effects of EPKINLY** include:

- tiredness
- muscle and bone pain
- injection site reactions
- fever
- stomach-area (abdominal) pain
- nausea
- diarrhea

These are not all the possible side effects of **EPKINLY**.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### General information about safe and effective use of EPKINLY.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about **EPKINLY** that is written for health professionals.

### What are the ingredients in EPKINLY?

**Active ingredient:** epcoritamab-bysp

**Inactive ingredients:** acetic acid, polysorbate 80, sodium acetate, sorbitol and Water for Injection.